Antibody-based immunosuppressive agents for corneal transplantation

M. A. Thiel, C. Kaufmann, D. J. Coster, K. A. Williams

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


The progress in antibody engineering over the last 20 years has created the tools for the development of novel antibody-based drugs and constructs, such as small antibody fragments, suitable for topical administration. In rheumatology, oncology, transplantation medicine and ophthalmology, therapeutic antibody constructs, and antibody fragments have been responsible for the clinical progress seen over the last decade. Although antibody-based therapies have become a well-established immunosuppressive option in solid organ transplantation, there are only very few reports with regard to corneal transplantation. The following review explains some of the important aspects of engineered antibody-based therapeutic agents and summarises the current use of such immunosuppressive therapies in transplantation medicine and corneal transplantation.

Original languageEnglish
Pages (from-to)1962-1965
Number of pages4
Issue number10
Publication statusPublished or Issued - Oct 2009
Externally publishedYes


  • Antibody
  • Corneal transplantation
  • Immunosuppression

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this